Who We Are

K. John Morrow Jr., PhD President/CEO Newport Biotech

K. John Morrow, Jr.

K. John Morrow, Jr.

My training is in the field of genetics (PhD, University of Washington, Seattle).  I did post doctoral study at the Istituto di Geneticà, Universitá di Pavia, Italy, and the Institute for Cancer Research (now the Fox Chase Cancer Center, Philadelphia PA). I have extensive experience in the academic community, including faculty positions at the University of Kansas and the Texas Tech University Health Sciences Center. I have authored over 60 peer-reviewed publications reporting original research in genetics, immunology, developmental biology, evolution, cancer biology and animal science.

I have been the principal investigator or co-principal investigator on over $2.5M of federal and privately funded research grants, and I was the principal investigator on a small business innovative research grant (SBIR) from the National Institutes of Health to Meridian Biosciences, Inc.

In addition to my academic experience, I have been associated with Meridian Bioscience, Inc., an immunodiagnostics firm located in Cincinnati, for the last 20  years. I was first Principle Investigator on a research project supported by the company, and later as Director of Biological Sciences Research at their Cincinnati facility. In addition to my involvement as a research scientist at Meridian, I have consulted for numerous private companies.

I serve on the editorial boards of Biopharm International http://www.biopharminternational.com/biopharm.

In 2009 I was awarded a Science Journalism Laureate for excellence in scientific writing from Purdue University.

I speak and write the Italian Language and work as a part time interpreter for Affordable Language Services in Cincinnati.

In 2016 I joined Point A Consulting (Louisville KY; http://pointaconsulting.com/ABOUT-POINT-A-CONSULTING) as part of a team evaluating an expansion proposal developed by a Southeastern US research institute. The study was completed and the Point A consulting team is now advising its clients on the specifics of its recommendations.

In December of 2016 I completed with Dr. Cheng Liu editorial work on a coillection of essays entitled "Biosimilars of Monoclonal Antibodies". The volume, published by John Wiley, is now available.  

On a personal note, my wife and I share a third floor early 20th century penthouse in Newport, Kentucky with four cats who are responsible for deciding critical issues.

Representative List of Publications

These are some of my writings, including books, peer-reviewed papers, editorial comment and articles in biotechnology trade papers.

271.  Morrow, K. J. 2013. Epigenetics drives pharma innovation: Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.  BioPharm International 26(1):22-23. http://digital.findpharma.com/nxtbooks/advanstar/biopharm0113/#/34.

 272.   Morrow, K. J. and Rathin Das. 2013. Therapeutic Antibodies in Review: Innovative products and a range of indications drive the therapeutic antibody market.  BioPharm International 26(2):34-40. http://www.biopharminternational.com/biopharm/Quality/Therapeutic-Antibodies-in-Review/ArticleStandard/Article/detail/804370.

 273. Morrow K. J. 2013. How Much Has the Human Genome Project Boosted the Economy? The Scientist (http://www.the-scientist.com/?articles.view/articleNo/35680/title/Opinion--The-Payoff-of-Big-Science/)

 274. Morrow, K. J. 2013 The Perils and Challenges of Building  a Biotech in Kentucky. Life Science Leader.  July.  https://www.lifescienceleader.com/docpreview/perils-and-challenges-of-building-a-biotech-in-kentucky-0001/%204f0e7e16-1f51-4ff2-970a-a1eb00c34049.

275.  Morrow, K. J. 2013. Scaleup issues for single use and steel. Genetic Engineering and Biotechnology News. October 15, 33(18):32-35.

276. Das, Rathin and  Morrow, K. J. 2013. Angiopoietins: Novel targets for anti-angiogenesis therapy.  BioPharm International 26(10):28-32. http://www.biopharminternational.com/biopharm/Feature+Articles/Angiopoietins-Novel-Targets-for-Anti-angiogenesis-/ArticleStandard/Article/detail/825085.

277. Morrow, K. J. and Sha, M. 2013. Vero Cell-based Vaccine Production: Rabies and Influenza: Cell lines, Media and Bioreactor Options. Eppendorf Newsletter. http://newbrunswick.eppendorf.com/en/more/tech-info/tech-papers.

278.  Morrow,  K. J. 2014. Evolva Turns Around Its Business Model: Swiss Biotech Opts Out Of Drug Development.  http://www.lifescienceleader.com/doc/evolva-turns-around-its-business-model-swiss-biotech-opts-out-of-drug-development-0001.

279. Morrow, K. J. 2014. Viral Clearance for Single Use and Steel. Genetic Engineering and Biotechnology News. October 15, 34(21):32-35.

280. Morrow, K. J. 2015. Seeded by Weeds: More than 50 years after cross-contamination of cultured cell lines was recognized, the problem continues to plague the scientific community. The Scientist. http://www.the-scientist.com/?articles.view/articleNo/42789/title/Seeded-by-Weeds/

281. Morrow, K. J. 2015. Drug Development In The Age Of Social Media. Life Science Leader. May, 2015.  http://www.lifescienceleader.com/doc/drug-development-in-the-age-of-social-media-0001

 282. Morrow, K. J. 2015. Boosting Upstream and Downstream Output Sartorius Stedim Biotech Forum Focuses On Next Level Bioprocess Operations. Genetic Engineering and Biotechnology News. Dec 5, 34(21):32-35.



 283. Morrow, K. J. 2016. Upstream Tools Hasten Product Development: Beware of Obstructions in the Upstream Processing of Biologics.  Genetic Engineering and Biotechnology News. Sep 15, 36(16):32-35. http://www.genengnews.com/gen-articles/upstream-tools-hasten-product-development/5837/?kwrd=morrow.

 284. Morrow, K. J. 2016. The Dark Side of CRISPR FrontLine Security 11:(4).  http://security.frontline.online/article/2016/4/5714-The-Dark-Side-of-CRISPR

285. Morrow, J. 2017. How A Biotech Startup Networked Through The Valley Of Death. Life Science Leader. July 2017.

Latest Book:

Cheng Liu (Editor), K. John Morrow, Jr. (Editor). Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. ISBN: 978-1-118-66231-1. 704 pages. December 2016. John Wiley and Sons, New York.


85. Morrow K. J. Combination Antibody Therapy for Cancer Treatment. Insight Pharma Reports. January 2016. http://www.insightpharmareports.com/Combination-Antibody-Therapy-Report/.

86. Cheng Liu (Editor), K. John Morrow, Jr. (Editor). Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development. ISBN: 978-1-118-66231-1. 704 pages. December 2016. John Wiley and Sons, New York.

Chapters in Books

71.  Deng, J.  X. K., Raju, T. S., and Morrow, K. J. 2004. Achieving Appropriate Glycosylation During the Scale-up of Antibody Production. In: Antibodies: Volume II, Novel Technologies and Therapeutic Use (ed: S. Subramarium) Kluver/Academic/Plenum Press. pp 53-78.

72. Morrow, K. J., and Dorsett, P. 2004. New Frontiers in Bioprocessing. IN: “Advances in Large Scale Biopharmaceutical Manufacturing and Scale-up Production.” Volume I. ASM Press, Rockville, MD, pp1-28.

73. Morrow, K.J., R. Bawa, and C. Wei. 2007. Recent advances in basic and clinical nanomedicine. In:  Medical Clinics of North America: Nanomedicine 91(5):805-844, Elsevier Inc., Philadelphia, PA.

74. Morrow, K. J. 2007 Advances in antibody manufacturing using mammalian cells. IN: Annual Review of Biotechnology 9:95-113. Editor: M. Raafat El-Gewely. Elsevier BV.

75. Morrow, K. J. 2007 Frontiers in Bioprocessing: 2006. IN: Advances in Biopharmaceutical Manufacturing. Editor: Eric S. Langer. (in Press), ASM Press.

Book Reviews

85. Morrow, K. J. “Recombinant Antibodies” by Breitling and Dubel. Quarterly Review of Biology 76(4):487, 2001.

86. Morrow, K. J. “Inside the FDA” by Fran Hawthorne. Biopharm International. June 2005.

Artist Elise Morrow

Elise contributed several figures for my book on Epigenetics, published in 2014.

I was born in Seattle, WA but spent many years living in Europe, Canada, and other parts of the US, where I studied studio art and art history.  Most recently, I made a full circle return to Seattle, where I have developed my mature technical skills and artistic vision through study at the Gage Academy under the instruction of Mark Kang-O'Higgins. Currently I am situated in my studio in the Sodo District in Seattle, concentrating on producing a new body of work for current and future shows and commissions. Please visit her website at www.elisemorrow.com

"I approach my work with what I call diffused realism, which involves
both intuitive manipulation and classical technique. I portray objects
connected by a dream-like symbolism, and which
hint at a world beyond that of our immediate perceptions."

Garima Naredi, graphic arist and web designer

Illustrator Garima Naredi

Garima also contributed to my book (published in 2014) with several graphic illustrations.

 Recently I have had the pleasure to work with several artists and scientists on a book that I am writing on the topic of epigenetics. One of them is Garima Naredi, who did several graphs and illustrations for the work. You can find more of her artistry at www.garimadesign.com and www.garimanaredi.com.

Garima introduces herself: I was born in India and lived there for most of my life. I hold a Bachelor's Degree in Visual Communications and I am currently working as a Freelance Graphic and Web Designer. My Seattle experience began in the year 2009 when I began training in the contemporary realist tradition of drawing and painting under artist Mark Kang O’Higgins. I practice as both a designer and artist from my studio in Seattle.

As an artist, I create narratives through figures and symbols. My mediums are oil and charcoal. I have realized that the narratives come to me in sync with my most all pervading thoughts a given time. Animal, bird and nature symbolism play a very important role in my work, which arises from the Hindu and native american concepts.

As a designer, I find challenges in information design to tell the story of a user, product or scenario. I design infographics, brand identities and websites with a focus on a clear and compelling representation of the client's information. I strive to make the interaction of the user with the design effective and meaningful.